Tzu-Po Chuang | Ruth Palmer Labhttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/tzu-po-chuang/Tzu-Po ChuangHugo Blox Builder (https://hugoblox.com)en-usMon, 10 Jun 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/media/icon_hua1ac8766117554d27209418f2eeeba33_52656_512x512_fill_lanczos_center_3.pngTzu-Po Chuanghttps://deploy-preview-3--ruthpalmerlab.netlify.app/author/tzu-po-chuang/Anaplastic Lymphoma Kinase signaling stabilizes SLC3A2 expression via MARCH11 to promote neuroblastoma cell growthhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/slc3a2/Mon, 10 Jun 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/slc3a2/ALK F1174S mutation impairs ALK kinase activity in EML4-ALK variant 1 and sensitizes EML4-ALK variant 3 to crizotinibhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_f1174s/Tue, 09 Jan 2024 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alk_f1174s/ALK fusion NSCLC oncogenes promote survival and inhibit NK cell responses via SERPINB4 expressionhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Tue, 21 Feb 2023 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkfusion_serpin/Novel human-derived EML4-ALK fusion cell lines identify ribonucleotide reductase RRM2 as a target of activated ALK in NSCLChttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/Thu, 01 Sep 2022 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/eml4_alk_rrm2/ALK ligand ALKAL2 potentiates MYCN-driven neuroblastoma in the absence of ALK mutationhttps://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/Mon, 01 Feb 2021 00:00:00 +0000https://deploy-preview-3--ruthpalmerlab.netlify.app/publication/alkal2_mycn/